Uncovering repurposed medicines to fight liver fibrosis
Summary
Geneticist Gary Peltz at Stanford University School of Medicine is utilizing Co-Scientist to accelerate the discovery of repurposed medicines for liver fibrosis, a scarring process causing over 1.4 million annual deaths. In research published in "Advanced Science", Peltz's team tasked Co-Scientist with proposing three drug candidates from existing literature, while Peltz himself selected two. All five drugs were tested on live human liver cells. Peltz's selections showed no benefit, whereas two of Co-Scientist's candidates successfully blocked fibrosis and promoted liver cell regeneration. Notably, one Co-Scientist pick, the cancer drug vorinostat, blocked 91% of a damage response linked to liver scarring. Co-Scientist's suggestions focused on drugs that reshape gene activity, rather than targeting single pathways, which Peltz believes could lead to a new generation of anti-fibrotic treatments.
Key takeaway
For research scientists engaged in drug discovery for complex diseases like liver fibrosis, consider integrating AI platforms such as Co-Scientist into your early-stage candidate identification. This approach can uncover effective repurposed drugs, like vorinostat, that target broad mechanisms such as gene activity modulation, potentially accelerating your pipeline and identifying treatments missed by traditional literature review. Prioritize validating AI-suggested candidates with robust in vitro models.
Key insights
AI-driven drug repurposing, specifically using Co-Scientist, effectively identifies novel anti-fibrotic drug candidates, outperforming human selection in initial tests.
Principles
- AI can uncover "needle in haystack" drug links.
- Gene activity modulation is a promising anti-fibrotic strategy.
- Repurposing existing drugs accelerates therapeutic discovery.
Method
Co-Scientist proposes drug candidates from literature, explaining reasoning. Human experts also select candidates. All are then validated using live human liver cell testbeds to assess fibrosis blocking and cell regeneration.
In practice
- Employ AI tools for drug repurposing candidate generation.
- Validate drug efficacy using live human cell testbeds.
- Investigate gene activity modulators for complex diseases.
Topics
- Liver Fibrosis
- Drug Repurposing
- Co-Scientist AI
- Vorinostat
- Gene Activity Modulation
- AI Drug Discovery
Best for: AI Scientist, Research Scientist
Related on AIssential
Editorial summary, takeaway, and curation by AIssential. Original article published by Google DeepMind News.